

Astellas Revises Consolidated Business Forecasts for the First Six Months of Fiscal Year 2011 ending March 31, 2012

Tokyo, October 28, 2011 — [Astellas Pharma Inc.](#) (Tokyo: 4503, “Astellas”) announced that, at a meeting of the Board of Directors held today, it was decided to revise the consolidated business forecasts for the first six months of fiscal year 2011 (“FY2011”, from April 1, 2011 to September 30, 2011) that were released on May 12, 2011. Details of the revision are provided below.

Details

1. Revision of Consolidated Business Forecasts for the First Six Months of FY2011 (from April 1, 2011 to September 30, 2011)

	Net sales (Millions of yen)	Operating income (Millions of yen)	Ordinary income (Millions of yen)	Net income (Millions of yen)	Net income per share (Yen)
Initial forecast (A)	478,000	71,000	72,000	39,000	84.45
Revised forecast (B)	483,900	82,900	82,400	51,300	111.08
Change (B-A)	+5,900	+11,900	+10,400	+12,300	
Change (%)	+1.2%	+16.8%	+14.4%	+31.5%	
(Reference) FY2010 First six months results	461,729	67,920	65,499	43,887	95.03

2. Reasons for Revision

Net sales is now expected to exceed its initial forecast for the following reasons: sales of Vesicare, a treatment for overactive bladder, increased globally, while sales of Prograf, the immunosuppressant, in Europe and sales of mainstay products in the Japanese market showed steady growth.

Also, operating income, ordinary income and net income are expected to exceed their respective initial forecasts. Gross profit is expected to exceed its initial forecast owing to the increase in net sales. In addition, research and development expenses is expected to be below its initial forecast because of the promotion of cost efficiency and the carry over of expenses into the third quarter or beyond. Additionally, for the second quarter of FY2011, a gain on sales of fixed assets of ¥10.0 billion is expected to be recorded as special gains following the sale of the property where the Tokyo Research Center was located.

Note that the initial consolidated business forecasts for FY2011 that were released on May 12, 2011 have not been revised and remain in effect. If it becomes necessary to change these business forecasts, Astellas will promptly announce the fact.

(Note) The above forecasts are based on the information currently available to management. Actual results may differ to the forecast figures.

###

For inquiries or additional information

Astellas Pharma Inc.

Corporate Communications

Tel: +81-3-3244-3201 Fax: +81-3-5201-7473

http://www.astellas.com/en
